Skip to main content
Top
Published in: Israel Journal of Health Policy Research 1/2017

Open Access 01-12-2017 | Integrative article

Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C

Authors: Nitzan Avisar, Yael Heller, Clara Weil, Aviva Ben-Baruch, Shani Potesman-Yona, Ran Oren, Gabriel Chodick, Varda Shalev, Nachman Ash

Published in: Israel Journal of Health Policy Research | Issue 1/2017

Login to get access

Abstract

Background

In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patients nationwide, risk-sharing agreements created an additional incentive to develop an innovative model for rapid treatment delivery.

Aim

This article aims to describe the development and implementation of a multi-disciplinary patient-centered model for the expedited provision of costly therapies in a community setting, based on experience delivering new HCV therapy in 2015.

Methods

We present the case of the Central District in Maccabi Healthcare Services (MHS), one of five districts in a 2-million-member healthcare provider. We describe the dimensions of the model and its implementation, including the composition and responsibilities of the multi-disciplinary team, screening for patient eligibility, provision of care, and barriers and facilitators identified at each stage.

Results

The experience of the MHS Central District indicates that good communication between all stakeholders was the key driver of successful implementation of the model. Overall, monthly treatment uptake increased following the intervention and by the end of 2015 a total of 99 patients were treated with OMB/PTV/r + DSV in this district. Early data indicate high effectiveness in this population and evaluation in ongoing.

Conclusions

This multi-disciplinary patient-centered model enabled rapid integration of screening and disease staging to identify and treat eligible HCV patients in the MHS central district. The model forms the basis of the 2017 project to deliver DAAs according to broader health basket criteria and may be adapted for the provision of other innovative health technologies in different healthcare settings.
Literature
1.
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.CrossRefPubMed
2.
go back to reference Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30–60.CrossRefPubMed Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30–60.CrossRefPubMed
3.
go back to reference Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotech. 2014;32(1):3–5.CrossRef Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotech. 2014;32(1):3–5.CrossRef
4.
go back to reference Afdhal N, Zeuzem S, Schooley R, Thomas D, Ward J, Litwin AH, Razavi H, Castera L, Poynard T, Muir A. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20(11):745–60.CrossRefPubMedPubMedCentral Afdhal N, Zeuzem S, Schooley R, Thomas D, Ward J, Litwin AH, Razavi H, Castera L, Poynard T, Muir A. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013;20(11):745–60.CrossRefPubMedPubMedCentral
5.
go back to reference Shani S, Siebzehner MI, Luxenburg O, Shemer J. Setting priorities for the adoption of health technologies on a national level—the Israeli experience. Health Policy. 2000;54(3):169–85.CrossRefPubMed Shani S, Siebzehner MI, Luxenburg O, Shemer J. Setting priorities for the adoption of health technologies on a national level—the Israeli experience. Health Policy. 2000;54(3):169–85.CrossRefPubMed
6.
go back to reference Triki N, Ash N, Porath A, Birnbaum Y, Greenberg D, Hammerman A. The evolution of risk-sharing agreements in the process of updating the National List of health Services in Israel. Value Health. 2016;19(7):A498–9.CrossRef Triki N, Ash N, Porath A, Birnbaum Y, Greenberg D, Hammerman A. The evolution of risk-sharing agreements in the process of updating the National List of health Services in Israel. Value Health. 2016;19(7):A498–9.CrossRef
7.
go back to reference Cohen R, Rabin H. Membership in sick funds 2015. Jerusalem: National Insurance Institute; 2016. Cohen R, Rabin H. Membership in sick funds 2015. Jerusalem: National Insurance Institute; 2016.
8.
go back to reference Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. J Med Virol. 2016;88(6):1044–50.CrossRefPubMed Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. J Med Virol. 2016;88(6):1044–50.CrossRefPubMed
9.
go back to reference Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, Landgraf A, Naggie S, Stout JE. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14(1):74.CrossRefPubMedPubMedCentral Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, Landgraf A, Naggie S, Stout JE. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis. 2014;14(1):74.CrossRefPubMedPubMedCentral
10.
go back to reference Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33.
11.
go back to reference Hawks L, Norton BL, Cunningham CO, Fox AD. The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat. 2016;23(6):473–8.CrossRefPubMedPubMedCentral Hawks L, Norton BL, Cunningham CO, Fox AD. The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat. 2016;23(6):473–8.CrossRefPubMedPubMedCentral
12.
go back to reference Do A, Lim JK. Epidemiology of nonalcoholic fatty liver disease: a primer. Clinical Liver Disease. 2016;7(5):106–8.CrossRef Do A, Lim JK. Epidemiology of nonalcoholic fatty liver disease: a primer. Clinical Liver Disease. 2016;7(5):106–8.CrossRef
13.
go back to reference Gray AL, Wirtz VJ, FM't Hoen E, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386(10004):1601–3. Gray AL, Wirtz VJ, FM't Hoen E, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386(10004):1601–3.
14.
go back to reference Weil C, Mehta D, Koren G, Pinsky B, Samp J, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: real-world data from a large healthcare provider. Journal of Viral Hepatitis. 2017 (in press) Weil C, Mehta D, Koren G, Pinsky B, Samp J, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: real-world data from a large healthcare provider. Journal of Viral Hepatitis. 2017 (in press)
15.
go back to reference Ellen ME, Horowitz E, Vaknin S, Lavis JN. Views of health system policymakers on the role of research in health policymaking in Israel. Israel J Health Pol Res. 2016;5(1):24.CrossRef Ellen ME, Horowitz E, Vaknin S, Lavis JN. Views of health system policymakers on the role of research in health policymaking in Israel. Israel J Health Pol Res. 2016;5(1):24.CrossRef
Metadata
Title
Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
Authors
Nitzan Avisar
Yael Heller
Clara Weil
Aviva Ben-Baruch
Shani Potesman-Yona
Ran Oren
Gabriel Chodick
Varda Shalev
Nachman Ash
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Israel Journal of Health Policy Research / Issue 1/2017
Electronic ISSN: 2045-4015
DOI
https://doi.org/10.1186/s13584-017-0172-1

Other articles of this Issue 1/2017

Israel Journal of Health Policy Research 1/2017 Go to the issue